Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Oxygen therapy shows promise in brain cancer fight

NCT ID NCT03862430

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times

Summary

This study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. NanO2 is designed to deliver more oxygen to tumors, which may make radiation work better. About 87 adults will take part, and researchers will track how long the cancer stays under control and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Atlantic Health System

    Summit, New Jersey, 07901, United States

  • Center for Neurosciences

    Tucson, Arizona, 85718, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Providence St. John's Cancer Institute

    Santa Monica, California, 90404, United States

  • Saint Luke's Cancer Institute

    Kansas City, Missouri, 64111, United States

  • St. Francis Medical Center, OSF Healthcare

    Peoria, Illinois, 61637, United States

  • UC Irvine Health- Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • University Hospitals Seidman Cancer Center

    Cleveland, Ohio, 44106, United States

  • University of Arizona

    Tucson, Arizona, 85719, United States

  • Yale Cancer Center

    New Haven, Connecticut, 06520, United States

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.